Mode of action of bronchodilators in COPD: Aims of their use and criteria of assessment;Mode d'action des bronchodilatateurs dans la BPCO: Objectifs de leur utilisation et critères d'évaluation

Presse Medicale

Volumn 33, Issue 2, 2004, Pages 104-110

  Roche, Nicolas ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; SALBUTAMOL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG UTILIZATION; DYSPNEA; EVALUATION; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LUNG FUNCTION TEST; LUNG INFLATION; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW; SMOKING CESSATION;

EID: 0842306982     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98498-9     Document Type: Review

References (54)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. National Heart Lung and Blood Institute. National Institute of Health. 1995. Global Initiative for Asthma; Global strategy for asthma management and prevention; NHLBI/WHO workshop report. Rep. 95-3659.
3. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 1995; 272: 1497-505.
4. Celli BR. The importance of spirometry in COPD and asthma: effect on approach to management. Chest 2000; 117: 155-95.
5. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117: 425-75.
6. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20.
7. Huchon G, Bernard JP, Bourcereau J et al. One year treatment with ipratropium bromide in symptomatic patients with chronic obstructive pulmonary disease, effects on clinical outcome (Sournis pour publication).
8. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-51.
9. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-75.
10. Taube C, Lehnigk B, Paasch K, Kirsten DK, Jorres RA, Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-20.
11. Pellegrino R, Rodarte JR, Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-12.
12. Tantucci C, Milic-Emili J. 2003. Mécanismes de l'obstruction des voies aériennes. In: Bronchopneumopathies chroniques obstructives, ed. G Huchon, N Roche, pp. 201-214. Paris: Editions Margaux Orange.
13. Maesen BL, Westermann CJ, Duurkens VA, van den Bosch JM. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 1103-8.
14. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112: 336-40.
15. Di Marco F, Milic-Emili J, Boveri B et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21: 86-94.
16. Hatipoglu U, Laghi F, Tobin MJ. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999; 160: 1916-21.
17. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-65.
18. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9.
19. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713-20.
20. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
21. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
22. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-7.
23. Jones PW, Koch P, Menjoge SS, Witek Jr TJ. Am J Respir Crit Care Med 2001; 163: A771.
24. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
25. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996; 63: 174-80.
26. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
27. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJJ. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-41.
28. Gallefoss F, Bakket PS. Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD-a 1-year follow-up randomized, controlled trial. Respir Med 2002; 96: 424-31.
29. Jarad NA, Wedzicka JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study group. Respir Med 1999; 93: 161-6.
30. O'Brien A, Russo-Magno P, Karki A et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001; 164: 365-71
31. Rice KL, Rubins JB, Lebahn F et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 2000; 162: 174-8.
32. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 3985-4015.
33. Burge PS, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 41: 46s-53s.
34. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000; 117: 545-75.
35. Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural and functional changes in the skeletal muscles of COPD patients: the "compartments" theory. Monaldi Arch Chest Dis 2001; 56: 214-24.
36. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2001; 2: 216-24.
37. Maltais F, Sullivan MJ, LeBlanc P et al. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J 1999; 13: 850-4.
38. Guell R, Casan R, Belda J et al. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest 2000; 117: 976-83.
39. Kirsten DK, Taube C, Lehnigk B, Jorres RA, Magnussen H. Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med 1998; 92: 1191-8.
40. Mahler DA, Horowitz MB. Clinical evaluation of exertional dyspnea. Clin Chest Med 1994; 15: 259-69.
41. Jones PW. Evaluation de l'obstruction bronchique: dyspnée, qualité de vie. Rev Mal Respir 1998; 15 Suppl 2: 525-8: 525-528.
42. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cuse 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
43. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9.
44. Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
45. Rutten-van MM, Roos B, van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995-1003.
46. Singh SJ, Sodergren SC, Hyland ME, Williams J, Morgan MD. A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med 2001; 95: 71-7.
47. Jones NL. 1988. Clinical exercise testing Philadelphia: WB Saunders.
48. Wasserman K, Hansen JE, Sue DY, Whipp BJ. 1987. Principles of exercise testing and interpretation. Lea & Febiger Edition.
49. Criner GJ, Cordova FC, Furukawa S et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 2018-27.
50. Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized Controlled Trial of Domiciliary Noninvasive Positive Pressure Ventilation and Physical Training in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2000; 162: 1335-41.
51. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54: 213-22.
52. Van Stel HF, Bogaard JM, Rijssenbeek-Nouwens LH, Colland VT. Multivariable assessment of the 6-min walking test in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1567-71.
53. Liesker JJ, Wijkstra PJ, ten Hacken NH, Koeter GH, Postma DS, Kerstjens HA. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
54. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.